Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators
AIT, dupilumab, and their combination improved clinical symptoms and quality of life in AD patients. AIT promoted allergen-specific IgG<sub>4</sub> production, while dupilumab modulated T cell responses and reduced allergen-specific IgE synthesis. The combination of AIT and dupilumab exhibited the immunological parameter changes characteristic of both treatments but did not result in a significantly greater improvement in AD symptoms.
Authors
- Le Li
- Nan Huang (ORCID: https://orcid.org/0000-0002-1102-7650)
- Dongxia Ma (ORCID: https://orcid.org/0000-0002-7415-3259)
- Rongfei Zhu (ORCID: https://orcid.org/0000-0003-2103-3381)
- Qingxiu Xu (ORCID: https://orcid.org/0009-0000-9950-891X)
- Yaqi Yang (ORCID: https://orcid.org/0000-0001-9460-6860)
- Lin Yang (ORCID: https://orcid.org/0000-0002-5183-2101)
- Liu Jin (ORCID: https://orcid.org/0009-0000-2964-0480)
- Wenjing Li (ORCID: https://orcid.org/0000-0002-8303-7604)
- Qing Jiang (ORCID: https://orcid.org/0000-0002-0579-8280)
- Yangxue Fu (ORCID: https://orcid.org/0009-0001-9531-7785)
- Hao Chen (ORCID: https://orcid.org/0000-0001-6959-5450)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- World Allergy Organization Journal
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.waojou.2025.101043
- Citations
- 2
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Bureau of Science and Technology of Zhoushan
- Wuhan Science and Technology Project